Received May 16, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | — | — |
Menveo, Administration of only the diluent portion; Menveo, Administration of only the diluent portion; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of inappropriate dose of vaccine administered in a male patient who received Men ACWY-CRM NVS (Menveo) for prophylaxis. On 07-MAY-2025, the patient received Menveo. On 07-MAY-2025, an unknown time after receiving Menveo, the patient experienced inappropriate dose of vaccine administered (Verbatim: Menveo, Administration of only the diluent portion) and inappropriate preparation of medication (Verbatim: Menveo, Administration of only the diluent portion). The outcome of the inappropriate dose of vaccine administered and inappropriate preparation of medication were not applicable. Additional Information: GSK receipt date: 07-MAY-2025 Other HCP reported about administration of only the diluent portion of Menveo (2 vial) to a patient, which led to Inappropriate preparation of medication and Inappropriate dose of vaccine administered. The pharmacist asked if the patient should be re vaccinated. The pharmacist did not provide patient identifiers (initials, age), and did not had the information about Menveo dose(lot number, expiration date). Consented to follow up.